Immuno-oncology for pancreatic cancer: a combination clinical trial with chemotherapy and radiation
Ended Project Grant Awarded Last action
- Award ID
- R44CA203336
- Recipient
-
Candel Therapeutics, Inc. UEI MPKRJM6FJFL8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,521,301
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Funding
-
- $2,909,951.00 Federal
- $611,350.00 Non-federal
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $611,350 | $0 | |
| Amendment | $611,350 | $611,350 | |
| Amendment | $611,350 | $0 | |
| Amendment | $116,400 | $0 | |
| Amendment | $659,516 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $17,534 | $0 | |
| Original award | $282,451 | $0 |
Quick answers
Who received award R44CA203336?
R44CA203336 was awarded to Candel Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on December 23, 2015.
How much is award R44CA203336 worth?
$3,521,301 has been obligated on R44CA203336: $2,909,951 in federal funding and $611,350 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award